CO6251285A2 - Derivado de tetrahidroisoquinolina novedoso - Google Patents

Derivado de tetrahidroisoquinolina novedoso

Info

Publication number
CO6251285A2
CO6251285A2 CO10131510A CO10131510A CO6251285A2 CO 6251285 A2 CO6251285 A2 CO 6251285A2 CO 10131510 A CO10131510 A CO 10131510A CO 10131510 A CO10131510 A CO 10131510A CO 6251285 A2 CO6251285 A2 CO 6251285A2
Authority
CO
Colombia
Prior art keywords
group
substituted
independently selected
substituents
cycloalkyl
Prior art date
Application number
CO10131510A
Other languages
English (en)
Inventor
Yoshikazu Uto
Hiroshi Karasawa
Kiyosumi Takaishi
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of CO6251285A2 publication Critical patent/CO6251285A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

1.- Un compuesto representado por la fórmula general (I):en donde R1 representa un grupo fenilaminocarbonilo que puede estar sustituido con 1 a 5 grupo(s) independientemente seleccionados del Grupo A de Sustituyentes, un grupo heteroarilaminocarbonilo que puede estar sustituido con 1 a 3 grupo(s) independientemente seleccionados del Grupo A de Sustituyentes, un grupo benzoxazol-2-ilo que puede estar sustituido con 1 a 3 grupo(s) independientemente seleccionados del Grupo A de Sustituyentes, un grupo benzotiazol-2-ilo que puede estar sustituido con 1 a 3 grupo(s) independientemente seleccionados del Grupo A de Sustituyentes, un grupo aminocarbonilo (alquilo de C1-C6 que puede estar monosustituido con un grupo cicloalquilo), un grupo aminocarbonilo (cicloalquilo de C3-C6) o un grupo adamantilaminocarbonilo; R2 independientemente representa un grupo alquilo de C1-C6; R3 representa un grupo heterocíclico que puede estar sustituido con 1 a 3 grupo(s) independientemente seleccionados de Grupo A de Sustituyentes, un grupo representado por la fórmula -C(=O)-O- R4 o un grupo representado por la fórmula C(=O)N(R5)R6; R4 representa un átomo de hidrógeno, un grupo alquilo de C1-C6 que puede estar sustituido con 1 a 3 grupo(s) independientemente seleccionados del Grupo B de Sustituyentes o un grupo cicloalquilo de C3-C6 que puede estar monosustituido con un grupo carboxilo; R5 representa un átomo de hidrógeno, un grupo alquilo de C1-C6 que puede estar sustituido con 1 a 3 grupo(s) independientemente seleccionados del Grupo B de Sustituyentes, un grupo cicloalquilo de C3-C6 que puede estar monosustituido con un grupo carboxilo o un grupo heterocíclico que puede estar sustituido con 1 a 3 grupo(s) independientemente seleccionados del Grupo A de Sustituyentes; R6 representa un átomo de hidrógeno, un grupo alquilo de C1-C6 que puede estar sustituido con 1 a 3 grupo(s) independientemente seleccionados del Grupo B de Sustituyentes o un grupo cicloalquilo de C3-C6 que puede estar monosustituido con un grupo carboxilo; ...
CO10131510A 2008-03-26 2010-10-22 Derivado de tetrahidroisoquinolina novedoso CO6251285A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008079901 2008-03-26

Publications (1)

Publication Number Publication Date
CO6251285A2 true CO6251285A2 (es) 2011-02-21

Family

ID=41113726

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10131510A CO6251285A2 (es) 2008-03-26 2010-10-22 Derivado de tetrahidroisoquinolina novedoso

Country Status (17)

Country Link
US (1) US8735425B2 (es)
EP (1) EP2256105B1 (es)
JP (2) JP4531127B2 (es)
KR (1) KR20100124771A (es)
CN (1) CN101981012A (es)
AU (1) AU2009230127B2 (es)
BR (1) BRPI0913986A2 (es)
CA (1) CA2719721C (es)
CO (1) CO6251285A2 (es)
IL (1) IL208168A (es)
MX (1) MX2010010471A (es)
MY (1) MY161992A (es)
NZ (1) NZ587630A (es)
RU (1) RU2474575C2 (es)
TW (1) TW200944505A (es)
WO (1) WO2009119534A1 (es)
ZA (1) ZA201006563B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5467862B2 (ja) 2006-03-31 2014-04-09 ノバルティス アーゲー 新規化合物
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
MY161992A (en) * 2008-03-26 2017-05-31 Daiichi Sankyo Co Ltd Novel tetrahydroisoquinoline derivative
US8507491B2 (en) 2008-08-25 2013-08-13 Irm Llc Compounds and compositions as hedgehog pathway inhibitors
NZ598535A (en) * 2009-08-28 2013-07-26 Daiichi Sankyo Co Ltd Novel tetrahydroisoquinoline compounds for the treatment of obesity and related conditions
WO2011123401A1 (en) * 2010-03-30 2011-10-06 Novartis Ag Uses of dgat1 inhibitors
FR2963005B1 (fr) * 2010-07-23 2012-08-17 Sanofi Aventis Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1077173A (en) 1965-03-19 1967-07-26 American Cyanamid Co Substituted alkylene piperidines and methods of preparation thereof
NL7800026A (nl) 1977-01-07 1978-07-11 Acna Werkwijze voor de bereiding van gesubstitueerde amino-benzenen.
GB8609630D0 (en) 1986-04-19 1986-05-21 Pfizer Ltd Anti-arrhythmia agents
US20010009912A1 (en) 1995-02-10 2001-07-26 Christos Tsaklakidis New derivatives of pyridil piperazine or pyridazinyl piperazyl, process for production thereof and medicaments containing these compounds
DZ2769A1 (fr) 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
JP2000026294A (ja) 1998-05-07 2000-01-25 Sankyo Co Ltd アリ―ルウレア又はアリ―ルメチルカルバモイル誘導体を含有する医薬
GB0028483D0 (en) * 2000-11-22 2001-01-10 Hoffmann La Roche Hydroxyethylamine HIV protease inhibitors
MXPA01012317A (es) 2000-12-28 2002-07-22 Warner Lambert Co Prueba de aciltransferasa del diacilglicerol (dgat).
US20020127626A1 (en) * 2001-01-05 2002-09-12 Sensors For Medicine And Science, Inc. Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
BR0214553A (pt) 2001-11-28 2004-10-13 Sod Conseils Rech Applic Compostos, processo de preparação, em fase lìquida, dos compostos, e, composições farmacêuticas
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
JP4231999B2 (ja) 2002-12-19 2009-03-04 ダイキン工業株式会社 ω−ヨウ化含フッ素アルキルビニルエーテルの製造方法
US7328301B2 (en) * 2003-04-07 2008-02-05 Intel Corporation Dynamically mapping block-alterable memories
EP1648457A2 (en) * 2003-07-22 2006-04-26 Merck & Co., Inc. Piperidine derivatives as melanocortin-4 receptor agonists
ES2397389T3 (es) 2003-07-30 2013-03-06 Xenon Pharmaceuticals Inc. Derivados de piridilo y su uso como agentes terapéuticos
KR101163800B1 (ko) 2003-10-15 2012-07-09 산텐 세이야꾸 가부시키가이샤 신규 인다졸 유도체
WO2005072740A2 (en) 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorectic compounds
ATE400567T1 (de) 2004-06-23 2008-07-15 Lilly Co Eli Kinaseinhibitoren
JP2006045209A (ja) 2004-07-02 2006-02-16 Sankyo Co Ltd ウレア誘導体
WO2006004200A1 (ja) * 2004-07-02 2006-01-12 Sankyo Company, Limited ウレア誘導体
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
JP2008521847A (ja) 2004-12-03 2008-06-26 エフ．ホフマン−ラ ロシュ アーゲー Ｈ３拮抗剤としての３−置換ピリジン誘導体
WO2006095922A1 (ja) * 2005-03-10 2006-09-14 Kyoto Pharmaceutical Industries, Ltd. テトラヒドロイソキノリン化合物およびその医薬用途
JP2007131584A (ja) 2005-11-11 2007-05-31 Sankyo Co Ltd 新規ベンゾオキサゾール誘導体
JP2007191471A (ja) * 2005-12-21 2007-08-02 Sankyo Co Ltd ウレア誘導体を含有する医薬
WO2007074753A1 (ja) * 2005-12-27 2007-07-05 Daiichi Sankyo Company, Limited 置換されたウレア誘導体を含有する医薬
EP1837332A1 (en) * 2006-03-23 2007-09-26 Laboratorios Del Dr. Esteve, S.A. Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments
MY161992A (en) * 2008-03-26 2017-05-31 Daiichi Sankyo Co Ltd Novel tetrahydroisoquinoline derivative

Also Published As

Publication number Publication date
US8735425B2 (en) 2014-05-27
JP4531127B2 (ja) 2010-08-25
CA2719721A1 (en) 2009-10-01
RU2474575C2 (ru) 2013-02-10
MX2010010471A (es) 2010-10-20
IL208168A0 (en) 2010-12-30
US20110034481A1 (en) 2011-02-10
CA2719721C (en) 2012-12-18
TW200944505A (en) 2009-11-01
EP2256105B1 (en) 2013-12-04
ZA201006563B (en) 2011-10-26
EP2256105A4 (en) 2011-09-14
NZ587630A (en) 2011-07-29
AU2009230127A1 (en) 2009-10-01
BRPI0913986A2 (pt) 2015-10-20
MY161992A (en) 2017-05-31
KR20100124771A (ko) 2010-11-29
JPWO2009119534A1 (ja) 2011-07-21
WO2009119534A1 (ja) 2009-10-01
EP2256105A1 (en) 2010-12-01
JP2010215640A (ja) 2010-09-30
CN101981012A (zh) 2011-02-23
IL208168A (en) 2013-04-30
RU2010143586A (ru) 2012-05-10
AU2009230127B2 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
CO6251285A2 (es) Derivado de tetrahidroisoquinolina novedoso
MX2018016267A (es) Metodo para producir derivado de piridona policiclica sustituida y cristal del mismo.
DOP2006000045A (es) Derivados del (1,5-difenil-1h-pirazol-3-il oxadiazol, su preparacion y su aplicacion en terapeutica
CY1119220T1 (el) Μονοκυκλικο παραγωγο πυριδινης
ECSP11010912A (es) Compuestos de pirrol
CO6270259A2 (es) Novedosos compuestos derivados de amina unidos con alcoxifenilo
CU20100021A7 (es) Derivado de oxopirazina y herbicida
GT200600134A (es) Compuestos novedosos de derivados de aminosulfonilo
RS53292B (en) CRYSTAL FORMS 2-THIAZOLYL-4-HINOLINYL-OXY DERIVATIVES, POWERFUL HCV INHIBITOR
CO6331462A2 (es) Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa
ECSP099324A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
AR077176A1 (es) Derivado de piridina que contiene un anillo ((fosfonooxi) metil) piridinio y agente antifungico que contiene este derivado
CO6341610A2 (es) Compuesto heterociclilo aromatico que contiene nitrogeno.
ES2553030T3 (es) Compuestos plaguicidas
CO6251235A2 (es) Compuestos derivados de azetidinas su preparacion y su aplicacion en terapeutica
CO2018010787A2 (es) Compuesto de griseofulvina
CO6460726A2 (es) Derivado de 5-hidroxi-pirimidin-4-carboxamida
MX2019007684A (es) Compuesto novedoso y sal de este aceptable desde el punto de vista farmacologico.
CO5700777A2 (es) Derivados de 4-(2-fenilsulfanil-fenil)-1,2,3,6-tetrahidropiridina como inhibidores de la recaptacion de serotonina
ECSP078009A (es) Derivados del 4,5-diarilpirrol, su preparación y su aplicación en terapéutica
AR083861A1 (es) OXAZOLIDINONAS COMO MODULADORES DE mGluR5 Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
CO2017003830A2 (es) Compuestos de piridina
CO6300944A2 (es) Derivado de hidroxi-quinoxalin-carboxamida
DOP2011000296A (es) Compuesto de pirazol
BR112018015552A2 (pt) novo composto de ácido bisfosfônico

Legal Events

Date Code Title Description
FC Application refused